Chia Soo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8351400/publications.pdf

Version: 2024-02-01

38 papers	2,257 citations	471509 17 h-index	315739 38 g-index
42 all docs	42 docs citations	42 times ranked	3733 citing authors

#	Article	IF	Citations
1	A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Engineering - Part B: Reviews, 2016, 22, 284-297.	4.8	741
2	Current development of biodegradable polymeric materials for biomedical applications. Drug Design, Development and Therapy, 2018, Volume 12, 3117-3145.	4.3	604
3	Craniosynostosis in transgenic mice overexpressing Nell-1. Journal of Clinical Investigation, 2002, 110, 861-870.	8.2	132
4	NELL-1 in the treatment of osteoporotic bone loss. Nature Communications, 2015, 6, 7362.	12.8	93
5	Tendinopathy: injury, repair, and current exploration. Drug Design, Development and Therapy, 2018, Volume 12, 591-603.	4.3	93
6	Fibromodulin promoted in vitro and in vivo angiogenesis. Biochemical and Biophysical Research Communications, 2013, 436, 530-535.	2.1	54
7	Human Perivascular Stem Cell-Based Bone Graft Substitute Induces Rat Spinal Fusion. Stem Cells Translational Medicine, 2014, 3, 1231-1241.	3.3	54
8	Brief Report: Human Perivascular Stem Cells andNel-Like Protein-1 Synergistically Enhance Spinal Fusion in Osteoporotic Rats. Stem Cells, 2015, 33, 3158-3163.	3.2	44
9	Fibromodulin Enhances Angiogenesis during Cutaneous Wound Healing. Plastic and Reconstructive Surgery - Global Open, 2014, 2, e275.	0.6	39
10	Fibromodulin Is Essential for Fetal-Type Scarless Cutaneous Wound Healing. American Journal of Pathology, 2016, 186, 2824-2832.	3.8	37
11	Fibromodulin reduces scar formation in adult cutaneous wounds by eliciting a fetal-like phenotype. Signal Transduction and Targeted Therapy, 2017, 2, .	17.1	37
12	Fibromodulin reprogrammed cells: A novel cell source for bone regeneration. Biomaterials, 2016, 83, 194-206.	11.4	29
13	Pericytes for the treatment of orthopedic conditions. , 2017, 171, 93-103.		29
14	Calvarial Defect Healing Induced by Small Molecule Smoothened Agonist. Tissue Engineering - Part A, 2016, 22, 1357-1366.	3.1	23
15	The pericyte antigen RGS5 in perivascular soft tissue tumors. Human Pathology, 2016, 47, 121-131.	2.0	22
16	Neurexin Superfamily Cell Membrane Receptor Contactin-Associated Protein Like-4 (Cntnap4) Is Involved in Neural EGFL-Like 1 (Nell-1)-Responsive Osteogenesis. Journal of Bone and Mineral Research, 2018, 33, 1813-1825.	2.8	22
17	Fibromodulin reduces scar size and increases scar tensile strength in normal and excessiveâ€mechanicalâ€loading porcine cutaneous wounds. Journal of Cellular and Molecular Medicine, 2018, 22, 2510-2513.	3.6	20
18	Neural EGFL like 1 as a potential pro-chondrogenic, anti-inflammatory dual-functional disease-modifying osteoarthritis drug. Biomaterials, 2020, 226, 119541.	11.4	18

#	Article	IF	Citations
19	Pharmacokinetics and osteogenic potential of PEGylated NELL-1 inÂvivo after systemic administration. Biomaterials, 2015, 57, 73-83.	11.4	12
20	NELL-1 expression in benign and malignant bone tumors. Biochemical and Biophysical Research Communications, 2015, 460, 368-374.	2.1	11
21	Pericytic mimicry in well-differentiated liposarcoma/atypical lipomatous tumor. Human Pathology, 2016, 54, 92-99.	2.0	11
22	Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion. American Journal of Pathology, 2017, 187, 1485-1495.	3.8	11
23	Neural EGFL-Like 1 Is a Downstream Regulator of Runt-Related Transcription Factor 2 in Chondrogenic Differentiation and Maturation. American Journal of Pathology, 2017, 187, 963-972.	3.8	11
24	The Effects of Systemic Therapy of PEGylated NEL-Like Protein 1 (NELL-1) on Fracture Healing in Mice. American Journal of Pathology, 2018, 188, 715-727.	3.8	11
25	Nfatc1 Is a Functional Transcriptional Factor Mediating Nell-1-Induced Runx3 Upregulation in Chondrocytes. International Journal of Molecular Sciences, 2018, 19, 168.	4.1	10
26	Physiological electric fields induce directional migration of mammalian cranial neural crest cells. Developmental Biology, 2021, 471, 97-105.	2.0	10
27	Neural EGFL-Like 1 Regulates Cartilage Maturation through Runt-Related Transcription Factor 3â€“Mediated Indian Hedgehog Signaling. American Journal of Pathology, 2018, 188, 392-403.	3.8	9
28	Peroxisome Proliferator-Activated Receptor-Î³ Knockdown Impairs Bone Morphogenetic Protein-2â€“Induced Critical-Size Bone Defect Repair. American Journal of Pathology, 2019, 189, 648-664.	3.8	8
29	Cumulative inactivation of Nell-1 in Wnt1 expressing cell lineages results in craniofacial skeletal hypoplasia and postnatal hydrocephalus. Cell Death and Differentiation, 2020, 27, 1415-1430.	11.2	8
30	Photopolymerizable Hydrogel-Encapsulated Fibromodulin-Reprogrammed Cells for Muscle Regeneration. Tissue Engineering - Part A, 2020, 26, 1112-1122.	3.1	8
31	Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation. BioResearch Open Access, 2016, 5, 159-170.	2.6	7
32	Sclerostin expression in skeletal sarcomas. Human Pathology, 2016, 58, 24-34.	2.0	7
33	Inactivation of Nell-1 in Chondrocytes Significantly Impedes Appendicular Skeletogenesis. Journal of Bone and Mineral Research, 2019, 34, 533-546.	2.8	7
34	High Resolution X-Ray: A Reliable Approach for Quantifying Osteoporosis in a Rodent Model. BioResearch Open Access, 2014, 3, 192-196.	2.6	4
35	Assessing the Bone-Forming Potential of Pericytes. Methods in Molecular Biology, 2021, 2235, 127-137.	0.9	3
36	Ang-1 and Ang-2 expression in angiomyolipoma and PEComa family tumors. Journal of Orthopaedics, 2017, 14, 154-160.	1.3	2

#	Article	IF	Citations
37	Ang-2 but not Ang-1 expression in perivascular soft tissue tumors. Journal of Orthopaedics, 2017, 14, 147-153.	1.3	2
38	Bioactive wound Closure Devices are highly Demanded. Clinics of Surgery, 2018, 1, .	0.0	0